Published in Vaccine on November 03, 2006
A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med (2009) 2.92
High IFN-γ and low SLPI mark severe asthma in mice and humans. J Clin Invest (2015) 1.74
Cyclic di-AMP: another second messenger enters the fray. Nat Rev Microbiol (2013) 1.69
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep (2015) 1.67
STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog (2014) 1.14
Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest (2015) 1.03
Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther Adv Vaccines (2013) 1.01
Current concepts of severe asthma. J Clin Invest (2016) 0.91
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol (2007) 0.90
Cyclic di-nucleotides: new era for small molecules as adjuvants. Microb Biotechnol (2011) 0.87
The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates pinocytosis-efficient cells in vivo. Elife (2015) 0.85
Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge. PLoS One (2014) 0.79
Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge. Hum Vaccin Immunother (2015) 0.77
Stimulation of innate immunity by in vivo cyclic di-GMP synthesis using adenovirus. Clin Vaccine Immunol (2014) 0.75
GGDEF and EAL domains inversely regulate cyclic di-GMP levels and transition from sessility to motility. Mol Microbiol (2004) 6.13
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood (2010) 3.58
Hierarchical involvement of various GGDEF domain proteins in rdar morphotype development of Salmonella enterica serovar Typhimurium. Mol Microbiol (2006) 2.18
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology (2010) 1.85
Establishment of a real-time PCR-based approach for accurate quantification of bacterial RNA targets in water, using Salmonella as a model organism. Appl Environ Microbiol (2004) 1.70
In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit. Nat Methods (2007) 1.64
Pseudomonas aeruginosa cupA-encoded fimbriae expression is regulated by a GGDEF and EAL domain-dependent modulation of the intracellular level of cyclic diguanylate. Environ Microbiol (2007) 1.50
Biosynthetic pathway of Pseudomonas aeruginosa 4-hydroxy-2-alkylquinolines. J Bacteriol (2005) 1.43
The missing link: Bordetella petrii is endowed with both the metabolic versatility of environmental bacteria and virulence traits of pathogenic Bordetellae. BMC Genomics (2008) 1.34
TGF-beta receptor signaling is critical for mucosal IgA responses. J Immunol (2004) 1.13
A chemical proteomics approach to identify c-di-GMP binding proteins in Pseudomonas aeruginosa. J Microbiol Methods (2011) 1.08
Quantitative determination of cyclic diguanosine monophosphate concentrations in nucleotide extracts of bacteria by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Anal Biochem (2008) 1.08
Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine (2011) 1.06
Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun (2007) 1.05
The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol (2002) 1.04
Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine. Infect Immun (2010) 1.04
The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol (2005) 1.03
Vaccines: from empirical development to rational design. PLoS Pathog (2012) 1.01
Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Hum Vaccin (2008) 0.97
Vaccine adjuvants: key tools for innovative vaccine design. Curr Top Med Chem (2013) 0.95
Intranasal vaccination with recombinant P6 protein and adamantylamide dipeptide as mucosal adjuvant confers efficient protection against otitis media and lung infection by nontypeable Haemophilus influenzae. J Infect Dis (2004) 0.95
The Toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur J Immunol (2004) 0.95
Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans. J Infect Dis (2003) 0.95
Molecular analysis of group B protective surface protein, a new cell surface protective antigen of group B streptococci. Infect Immun (2002) 0.94
Dendritic cell-mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation. J Immunol (2014) 0.94
Effects of aging on influenza virus infection dynamics. J Virol (2014) 0.94
Dual role colonization factors connecting Vibrio cholerae's lifestyles in human and aquatic environments open new perspectives for combating infectious diseases. Curr Opin Biotechnol (2008) 0.94
Lymph node-derived lymphatic endothelial cells express functional costimulatory molecules and impair dendritic cell-induced allogenic T-cell proliferation. FASEB J (2012) 0.93
Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. Hepatology (2009) 0.93
Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol (2004) 0.93
Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete. J Biol Chem (2008) 0.92
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin Vaccine Immunol (2007) 0.90
Multiple-locus variable-number tandem-repeat analysis for clonal identification of Vibrio parahaemolyticus isolates by using capillary electrophoresis. Appl Environ Microbiol (2009) 0.89
Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. Eur J Immunol (2003) 0.89
Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. Infect Immun (2006) 0.88
HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. Hum Gene Ther (2013) 0.88
An SopB-mediated immune escape mechanism of Salmonella enterica can be subverted to optimize the performance of live attenuated vaccine carrier strains. Microbes Infect (2006) 0.88
Gene expression profiles of T cells from hepatitis E virus infected patients in acute and resolving phase. J Clin Immunol (2011) 0.87
Intranasal formulations: promising strategy to deliver vaccines. Expert Opin Drug Deliv (2014) 0.87
Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine (2008) 0.87
Cyclic di-nucleotides: new era for small molecules as adjuvants. Microb Biotechnol (2011) 0.87
The member of the cyclic di-nucleotide family bis-(3', 5')-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant. Vaccine (2010) 0.87
An aromatic amino acid auxotrophic mutant of Bordetella bronchiseptica is attenuated and immunogenic in a mouse model of infection. FEMS Microbiol Lett (2003) 0.86
A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties. J Immunol (2007) 0.86
Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine (2005) 0.86
The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant. Vaccine (2005) 0.86
HIV-1 matrix protein p17 promotes lymphangiogenesis and activates the endothelin-1/endothelin B receptor axis. Arterioscler Thromb Vasc Biol (2014) 0.85
Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection. J Infect Dis (2010) 0.85
Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization. Vaccine (2013) 0.85
Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.85
Characterization of a B220+ lymphoid cell subpopulation with immune modulatory functions in nasal-associated lymphoid tissues. J Immunol (2005) 0.84
Block of death-receptor apoptosis protects mouse cytomegalovirus from macrophages and is a determinant of virulence in immunodeficient hosts. PLoS Pathog (2012) 0.84
Ectopic expression of murine CD47 minimizes macrophage rejection of human hepatocyte xenografts in immunodeficient mice. Hepatology (2012) 0.84
Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17. Vaccine (2008) 0.83
Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein. Vaccine (2003) 0.82
A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses (2012) 0.82
Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice. Curr Cancer Drug Targets (2008) 0.81
Characterization of a novel intracellularly activated gene from Salmonella enterica serovar typhi. Infect Immun (2002) 0.80
Toll-like receptor-2 agonist-allergen coupling efficiently redirects Th2 cell responses and inhibits allergic airway eosinophilia. Am J Respir Cell Mol Biol (2012) 0.80
Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoS One (2010) 0.80
Variation in the 16S-23S rRNA intergenic spacer regions in Vibrio parahaemolyticus strains are due to indels nearby their tRNAGlu. FEMS Microbiol Lett (2006) 0.80
Identification of the domains of the fibronectin-binding protein I of Streptococcus pyogenes responsible for adjuvanticity. FEMS Immunol Med Microbiol (2003) 0.79
Analysis of Wuchereria bancrofti infections in a village community in northern Nigeria: increased prevalence in individuals infected with Onchocerca volvulus. Parasitol Int (2003) 0.79
The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect Immun (2004) 0.79
Development and characterization of attenuated metabolic mutants of Bordetella bronchiseptica for applications in vaccinology. Environ Microbiol (2012) 0.79
Identification of B- and T-cell epitopes within the fibronectin-binding domain of the SfbI protein of Streptococcus pyogenes. Infect Immun (2003) 0.78
Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes. Vaccine (2006) 0.78
Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain. Vaccine (2005) 0.78
Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Adv Exp Med Biol (2009) 0.78
Selective hydroxylation of highly branched fatty acids and their derivatives by CYP102A1 from Bacillus megaterium. Chembiochem (2006) 0.78
Immune modulator adamantylamide dipeptide stimulates efficient major histocompatibility complex class I-restricted responses in mice. Clin Vaccine Immunol (2007) 0.77
Rodents as pre-clinical models for predicting vaccine performance in humans. Expert Rev Vaccines (2015) 0.77